One-Month DAPT in CABG Patients
Part of paid clinical trials in Englewood, New Jersey.
- Sponsor
- Weill Medical College of Cornell University
- Study ID
- NCT05997693
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Chronic Coronary Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ticagrelor 90 MG — DRUGTicagrelor 90 mg twice daily taken orally for one month
- Low-dose aspirin — DRUG75-150 mg once daily taken orally
Study Details
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Key Dates
- Start date
- Aug 15, 2024
- Status verified
- Dec 2025
- Primary completion
- Jan 31, 2027
- Completion
- Jan 31, 2031
Study Design
- Enrollment
- 700 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Ticagrelor 90 mg + Low-Dose Aspirin
- Active Comparator: Low-Dose Aspirin Alone
Primary Outcome Measure
Hierarchical composite of time to death, stroke, myocardial infarction, repeat revascularization and any graft failure. [ Time Frame: 1 year ]
Central Contacts
- Trisha Ali-Shaw646-962-8281
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Englewood Hospital | Englewood | New Jersey | 07631 | Molly Schultheis, MD (PRINCIPAL_INVESTIGATOR) |
| NewYork-Presbyterian: Queens Hospital | Flushing | New York | 11355 | Charles A Mack, MD (PRINCIPAL_INVESTIGATOR) |
| Weill Cornell Medicine | New York | New York | 10065 | Mario Gaudino, MD PhD (PRINCIPAL_INVESTIGATOR) |